Getting a Grip on Streptococcus

If biotechnology as a science and as an industry has "grown up" over the past 20 years, the search for a vaccine against the Streptococcus A bacterium may be described as "coming of age." The bacterium presents a serious challenge. In children, it infects the mouth, nose, and throat and can cause the painful inflammation of strep throat. But it can have more dire consequences--if an infected child doesn't receive adequate antibiotic treatment, the infection could find its way into the bloodstre

Written byJames Kling
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

If biotechnology as a science and as an industry has "grown up" over the past 20 years, the search for a vaccine against the Streptococcus A bacterium may be described as "coming of age."

The bacterium presents a serious challenge. In children, it infects the mouth, nose, and throat and can cause the painful inflammation of strep throat. But it can have more dire consequences--if an infected child doesn't receive adequate antibiotic treatment, the infection could find its way into the bloodstream. The result is an antibody response that goes beyond the mouth and nose, with antibodies against Streptococcus A circulating in the bloodstream. At least some of those antibodies are cross-reactive to human tissue in the heart, kidneys, and brain, and they may cause heart damage known as acute rheumatic fever.

Milan Blake, senior director of molecular biology and protein chemistry at North American Vaccines, is pictured with his ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies